Flag of the European Union EU Clinical Trials Register Help

Clinical trials for nivolumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    446 result(s) found for: nivolumab. Displaying page 3 of 23.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-002643-28 Sponsor Protocol Number: CA209-8JD Start Date*: 2019-02-25
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction.
    Medical condition: Stage III/IV resectable oral squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000626-60 Sponsor Protocol Number: UC-0130/1804 Start Date*: 2019-01-08
    Sponsor Name:UNICANCER
    Full Title: A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer.
    Medical condition: High risk Human Papilloma Virus (HPV)-driven oropharynx cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003935-20 Sponsor Protocol Number: N14MPN Start Date*: 2015-07-02
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study
    Medical condition: A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10027408 Mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000058-24 Sponsor Protocol Number: Connect&Go Start Date*: Information not available in EudraCT
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.
    Medical condition: Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003729-41 Sponsor Protocol Number: CA209-915 Start Date*: Information not available in EudraCT
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.
    Medical condition: Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10040891 Skin melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended) Outside EU/EEA RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-003626-40 Sponsor Protocol Number: CA209-274 Start Date*: 2016-07-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
    Medical condition: Subjects with High Risk Invasive Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001188-26 Sponsor Protocol Number: CA052-002 Start Date*: 2022-03-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
    Medical condition: Male and female participants ≥ 18 years of age with advanced or metastatic cancers
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001402-41 Sponsor Protocol Number: GS-US-296-2013 Start Date*: 2017-01-31
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroeso...
    Medical condition: unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001230-34 Sponsor Protocol Number: CA209-76K Start Date*: 2019-08-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb ...
    Medical condition: Completely resected Stage IIb/c melanoma subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) CZ (Ongoing) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) Outside EU/EEA RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003939-30 Sponsor Protocol Number: CA209-142 Start Date*: 2014-03-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
    Medical condition: MSI Positive Colorectal Cancer MSI Negative Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) IE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001830-24 Sponsor Protocol Number: CA209-9N9 Start Date*: 2021-04-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2021-003477-61 Sponsor Protocol Number: 20210098 Start Date*: 2022-07-13
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Canc...
    Medical condition: Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    23.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084227 Gastroesophageal junction cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001645-64 Sponsor Protocol Number: CA209-714 Start Date*: 2016-10-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcin...
    Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IE (Completed) BE (Completed) NL (Completed) SE (Completed) NO (Completed) GB (GB - no longer in EU/EEA) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001514-20 Sponsor Protocol Number: CA209-648 Start Date*: 2017-06-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent o...
    Medical condition: Inoperable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DK (Completed) PT (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004527-23 Sponsor Protocol Number: MM1636 Start Date*: 2017-03-14
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004916-76 Sponsor Protocol Number: TWINS-GU002 Start Date*: 2020-07-16
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: A phase II study of nivolumab combined with metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients.
    Medical condition: Patients with advanced renal cell carcinoma pre-treated with VEGFR inhibitors.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002893-38 Sponsor Protocol Number: CA209-8PA Start Date*: 2019-03-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients
    Medical condition: Advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001447-31 Sponsor Protocol Number: 2018/2706 Start Date*: 2018-08-02
    Sponsor Name:Gustave Roussy
    Full Title: Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consol...
    Medical condition: Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) NL (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004567-31 Sponsor Protocol Number: XL184–313 Start Date*: 2019-09-04
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or M...
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) HU (Completed) BE (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004633-27 Sponsor Protocol Number: CA209384 Start Date*: 2016-05-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Receive...
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) AT (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:14:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA